Table 1 Comparison of clinical and laboratory features between LEP hypermethylated and non-hypermethylated AML patients

Sex, male/female

35/33

69/35

Median age, years (range)

55.5 (18–85)

55 (18–86)

Median WBC, × 10⁹/L (range)

12.5 (0.9–528.0)

18.4 (0.3–232.1)

Median hemoglobin, g/L (range)

76 (32–147)

79 (32–144)

Median platelets, × 10⁹/L (range)

50 (6–447)

38.3 (3–415)

Median BM blasts, % (range)

45 (5.5–97.5)

56.5 (1–99)

FAB classifications

 M0

0

2

 M1

5

6

 M2

21

45

 M3

19

10

 M4

15

20

 M5

7

14

 M6

1

5

 No data

0

2

Karyotypes

 Normal

24

52

 t(8;21)

4

8

 inv(16)

0

2

 t(15;17)

19

8

 +8

2

3

 -5/5q-

1

0

 -7/7q-

0

1

 t(9;22)

1

1

 11q23

0

2

 Complex

7

10

 Others

7

9

 No data

3

8

Gene mutations

 CEBPA (±)

4/53

12/69

 NPM1 (±)

5/52

10/71

 FLT3-ITD (±)

4/53

8/73

 C-KIT (±)

5/52

3/78

 N/K-RAS (±)

3/54

12/69

 IDH1/2 (±)

3/54

2/79

 DNMT3A (±)

2/55

6/75

 U2AF1 (±)

0/57

3/78

 SRSF2 (±)

3/54

1/80

 SETBP1 (±)

0/57

2/79

CR, total AML (±)

33/26

29/56

CR, non-M3 AML (±)

20/22

23/56

CR, CN-AML (±)

11/9

14/29